Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Bayer AG

Healthcare US BAYZF

38.94USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

40.6140.61
LowHigh

52 Week Range

24.9058.33
LowHigh

Fundamentals

  • Previous Close 38.94
  • Market Cap46777.31M
  • Volume500
  • P/E Ratio-
  • Dividend Yield0.23%
  • EBITDA8869.00M
  • Revenue TTM45575.00M
  • Revenue Per Share TTM46.39
  • Gross Profit TTM 27048.00M
  • Diluted EPS TTM-4.32

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -3129.00000M -2334.00000M -1621.00000M 4670.00M 2046.00M
Minority interest -25.00000M -6.00000M 1.00M -16.00000M -22.00000M
Net income -3620.00000M -2552.00000M -2941.00000M 4150.00M 1000.00M
Selling general administrative 14709.00M 15938.00M 14935.00M 16922.00M 15325.00M
Selling and marketing expenses - - - - -
Gross profit 26778.00M 25336.00M 27888.00M 30868.00M 27265.00M
Reconciled depreciation 2785.00M 8783.00M 10020.00M 6503.00M 3056.00M
Ebit - - - 9121.00M 7475.00M
Ebitda - - - 13030.00M 6449.00M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 6139.00M 3327.00M 8036.00M 7333.00M 6909.00M
Other operating expenses - - - 528.00M -296.00000M
Interest expense 2265.00M 2358.00M 2047.00M 1857.00M 1347.00M
Tax provision 466.00M 212.00M 1321.00M 504.00M 1024.00M
Interest income 471.00M 521.00M 484.00M 379.00M 346.00M
Net interest income -1857.00000M -1897.00000M -1611.00000M -1823.00000M -945.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 504.00M 1024.00M
Total revenue 45575.00M 46606.00M 47637.00M 50739.00M 44081.00M
Total operating expenses 39436.00M 43279.00M 39601.00M 43406.00M 37172.00M
Cost of revenue 18797.00M 21270.00M 19749.00M 19871.00M 16816.00M
Total other income expense net - - - - -
Discontinued operations - - - - -
Net income from continuing ops -3595.00000M -2546.00000M -2942.00000M 4166.00M 1022.00M
Net income applicable to common shares - - - 4150.00M 1000.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 104541.00M 110850.00M 116259.00M 124877.00M 120241.00M
Intangible assets 20622.00M 22112.00M 23363.00M 24183.00M 26258.00M
Earning assets - - - - -
Other current assets - - - 521.00M 545.00M
Total liab 78478.00M 78805.00M 83181.00M 85951.00M 87073.00M
Total stockholder equity 26063.00M 32045.00M 32927.00M 38773.00M 33020.00M
Deferred long term liab - - - 3797.00M 4312.00M
Other current liab 1180.00M 401.00M 567.00M 16105.00M 17097.00M
Common stock - - - 2515.00M 2515.00M
Capital stock 2515.00M 2515.00M 2515.00M 2515.00M 2515.00M
Retained earnings - - - 17233.00M 13345.00M
Other liab - - - 17076.00M 21189.00M
Good will 28061.00M 30016.00M 32299.00M 39648.00M 40106.00M
Other assets - - - 10481.00M 10299.00M
Cash 6671.00M 6191.00M 5907.00M 5171.00M 4564.00M
Cash and equivalents - - - - -
Total current liabilities 32585.00M 28952.00M 29457.00M 35084.00M 29403.00M
Current deferred revenue - - - - -
Net debt 28496.00M 33258.00M 35729.00M 34915.00M 33802.00M
Short term debt - - - - -
Short long term debt 4388.00M 4897.00M 4410.00M 7257.00M 2817.00M
Short long term debt total - - - - -
Other stockholder equity - - - 19025.00M 17160.00M
Property plant equipment - - - 13674.00M 12688.00M
Total current assets 32911.00M 34444.00M 37556.00M 37760.00M 32578.00M
Long term investments - - - - -
Net tangible assets - - - -21294.00000M -29044.00000M
Short term investments 1185.00M 1896.00M 4680.00M 4982.00M 3175.00M
Net receivables 9077.00M 8966.00M 9343.00M 13450.00M 12980.00M
Long term debt 30779.00M 34552.00M 37226.00M 32829.00M 35549.00M
Inventory 12335.00M 13403.00M 13929.00M 13636.00M 11314.00M
Accounts payable 7081.00M 7518.00M 7456.00M 7545.00M 6792.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 71630.00M 76406.00M 78703.00M 87117.00M 87663.00M
Capital lease obligations 1286.00M 1248.00M 1238.00M 1234.00M 1165.00M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 661.00M 2325.00M -306.00000M -2978.00000M 4302.00M
Change to liabilities - - - 612.00M 854.00M
Total cashflows from investing activities - - - -2381.00000M 855.00M
Net borrowings -2045.00000M -5018.00000M 3253.00M -974.00000M -2452.00000M
Total cash from financing activities - - - -4220.00000M -5645.00000M
Change to operating activities - - - -1407.00000M 436.00M
Net income -3620.00000M -2552.00000M -2941.00000M 4150.00M 1000.00M
Change in cash 776.00M 354.00M 921.00M 607.00M 373.00M
Begin period cash flow 6191.00M 5907.00M 5171.00M 4564.00M 4191.00M
End period cash flow 6671.00M 6191.00M 5907.00M 5171.00M 4564.00M
Total cash from operating activities 5930.00M 7368.00M 5117.00M 7093.00M 5089.00M
Issuance of capital stock - 0.00000M 23.00M - -
Depreciation 2785.00M 8783.00M 10020.00M 3949.00M 3740.00M
Other cashflows from investing activities - - - 218.00M 137.00M
Dividends paid -127.00000M -131.00000M -2379.00000M -1985.00000M -1993.00000M
Change to inventory 475.00M 521.00M -430.00000M -2170.00000M -173.00000M
Change to account receivables - - - 269.00M -61.00000M
Sale purchase of stock -14.00000M -16.00000M -24.00000M - -
Other cashflows from financing activities - - - -1251.00000M -1200.00000M
Change to netincome - - - 1690.00M -707.00000M
Capital expenditures 2487.00M 2778.00M 2751.00M 2949.00M 2611.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 5934.00M 85.00M -4065.00000M -2696.00000M 1056.00M
Stock based compensation - - - - -
Other non cash items 1857.00M 1897.00M 1611.00M 2342.00M 1307.00M
Free cash flow 3443.00M 4590.00M 2366.00M 4144.00M 2478.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BAYZF
Bayer AG		 - -% 38.94 - 9.36 1.03 1.55 1.52 36.04
LLY
Eli Lilly and Company		 14.63 1.37% 1078.78 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 0.35 0.16% 223.24 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 1.73 0.80% 217.13 86.32 14.33 5.89 50.46 7.04 24.44
AZN
AstraZeneca PLC		 -1.17 0.66% 176.28 30.69 19.23 5.30 6.45 5.72 17.23

Reports Covered

Stock Research & News

View All

Profile

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Bayer AG

Kaiser-Wilhelm-Allee 1, Leverkusen, Germany, 51368

Key Executives

Name Title Year Born
Mr. Werner Baumann Chairman of Management Board, CEO & Chief Sustainability Officer 1962
Mr. Wolfgang U. Nickl CFO & Member of Management Board 1969
Mr. Heiko W. J. Schipper Member of Management Board & Pres of the Consumer Health Division 1969
Mr. Stefan Oelrich Head of the Pharmaceuticals Division & Member of the Board of Management 1968
Ms. Sarena S. Lin Chief Transformation & Talent Officer, Labor Director and Member of Management Board 1971
Mr. Rodrigo Santos Member of Management Board & Pres of the Crop Science Division 1973
Mr. Bernd-Peter Bier Head of Accounting and Head of Taxes 1967
Mr. Oliver Maier Head of Investor Relations NA
Dr. Gabriel Harnier Head of Law, Patents & Compliance 1971
Mr. Michael Preuss Head of Communications, Gov. Relations and Corp. Brand NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.